Richard Finkel, MD, a pediatric neurologist at St. Jude Children’s Research Hospital, was included in the Time100 Health list ...

He had a hunch that the oral SMA treatment risdiplam, made by Roche, had prenatal potential because it’s safe for kids and ...

Hence, statement 2 is correct. — Scientists utilised an oral medication called risdiplam, which is prescribed to patients to ...

As scientists explore treating genetic disorders before birth, the promise of foetal gene therapy is growing—but there are ...

The phase 2 PIVOT-HD trial of Novartis-partnered PTC518 (votoplam) showed that the oral mRNA splicing modifier was able to ...

Kesar Petroproducts Ltd today announced that it has started commercial production at its new fertiliser plant in Ratnagiri, ...

In a strong start to FY'26, MOIL has reported its highest ever April performance, reinforcing its commitment to operational ...

In February 2025, researchers at St Jude Children’s Research Hospital reported the first known in utero use of Roche’s spinal muscular atrophy (SMA) drug Evrysdi (risdiplam) in a human foetus.

A modeling study predicts a resurgence of previously eliminated infectious diseases, including measles, rubella, poliomyelitis and diphtheria, if current child vaccination rates continue to fall ...

Full-year 2025 guidance 2 raised: Sales expected to grow high single digit, core operating income expected to grow low double-digit ...

0.51 points in the sham control arm. In addition, in the Phase IIIb STRENGTH study, treatment with OAV101 IT in patients who have discontinued treatment with nusinersen or risdiplam demonstrated ...